Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade F 9.85 3.96% 0.38
CLVS closed up 3.96 percent on Friday, January 17, 2020, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical CLVS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
50 DMA Resistance Bearish 3.96%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.96%
Narrow Range Bar Range Contraction 3.96%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Disease Chemical Compounds Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Lactams Treatment Of Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds

Is CLVS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.05
52 Week Low 2.93
Average Volume 13,037,382
200-Day Moving Average 10.81
50-Day Moving Average 9.79
20-Day Moving Average 10.16
10-Day Moving Average 9.40
Average True Range 1.22
ADX 17.99
+DI 30.44
-DI 20.63
Chandelier Exit (Long, 3 ATRs ) 8.93
Chandelier Exit (Short, 3 ATRs ) 11.76
Upper Bollinger Band 12.13
Lower Bollinger Band 8.18
Percent B (%b) 0.42
BandWidth 38.93
MACD Line -0.25
MACD Signal Line -0.10
MACD Histogram -0.1446
Fundamentals Value
Market Cap 481.05 Million
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -1.11
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.10
Resistance 3 (R3) 11.07 10.63 10.89
Resistance 2 (R2) 10.63 10.31 10.64 10.82
Resistance 1 (R1) 10.24 10.12 10.44 10.27 10.75
Pivot Point 9.80 9.80 9.90 9.81 9.80
Support 1 (S1) 9.41 9.48 9.61 9.44 8.95
Support 2 (S2) 8.97 9.29 8.98 8.88
Support 3 (S3) 8.58 8.97 8.81
Support 4 (S4) 8.61